Kết quả điều trị Paclitaxel trong ung thư thực quản giai đoạn tiến triển di căn kháng Platinum

Abstract

This retrospective, descriptive study evaluated 67 patients with advanced or metastatic platinum-resistant esophageal cancer treated with paclitaxel. The study aimed to describe baseline clinical characteristics and evaluate treatment outcomes. In the study cohort, 32.8% of patients presented with metastatic disease at initial diagnosis, while 67.2% developed metastasis after curative-intent treatment. The objective response rate was 10.4%, the stable disease rate was 40.3%, and the disease control rate was 50.7%. The median progression-free survival (mPFS) was 3,1 months, and the median overall survival (mOS) was 6.0 months. Subgroup analysis revealed that the relative dose intensity of paclitaxel significantly influenced mPFS (p = 0.006). Toxicity was predominantly mild to moderate (grade 1–2), with anemia being the most common adverse event (35.8%). No grade 4 toxicities or treatment-related deaths were observed. Paclitaxel demonstrated meaningful clinical benefit with acceptable tolerability. Therefore, this regimen represents a feasible treatment option for patients with platinum-resistant advanced or metastatic esophageal cancer in the current clinical setting in Vietnam.